Clearside Biomedical (NASDAQ:CLSD – Get Free Report) announced its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03, Zacks reports.
Clearside Biomedical Stock Performance
CLSD traded up $0.01 during trading on Thursday, reaching $1.03. 151,241 shares of the company’s stock were exchanged, compared to its average volume of 356,917. The firm has a market capitalization of $78.12 million, a PE ratio of -2.29 and a beta of 2.10. Clearside Biomedical has a fifty-two week low of $0.77 and a fifty-two week high of $1.76. The company’s fifty day moving average price is $0.96 and its 200-day moving average price is $1.05.
Analyst Upgrades and Downgrades
CLSD has been the topic of several research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research note on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research note on Thursday, March 6th. Finally, StockNews.com lowered shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $5.75.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Further Reading
- Five stocks we like better than Clearside Biomedical
- What is Forex and How Does it Work?
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- What is a Death Cross in Stocks?
- Top 3 Beverage Stocks Pouring Out Profits
- Growth Stocks: What They Are, Examples and How to Invest
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
